Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLuk, Ian Y.
dc.contributor.authorJenkins, Laura J.
dc.contributor.authorSchoffer, Kael
dc.contributor.authorNg, Irvin
dc.contributor.authorTse, Janson W. T.
dc.contributor.authorMouradov, Dmitri
dc.contributor.authorArango Corro, Diego
dc.contributor.authorDopeso Gonzalez, J Higinio
dc.date.accessioned2022-11-04T08:43:58Z
dc.date.available2022-11-04T08:43:58Z
dc.date.issued2022-11
dc.identifier.citationLuk IY, Jenkins LJ, Schoffer KL, Ng I, Tse JWT, Mouradov D, et al. Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression. Cell Death Differ. 2022 Nov;29:2288–02.
dc.identifier.issn1476-5403
dc.identifier.urihttps://hdl.handle.net/11351/8392
dc.descriptionEpigenetics; Tumour-suppressor proteins
dc.description.abstractColorectal cancers (CRCs) often display histological features indicative of aberrant differentiation but the molecular underpinnings of this trait and whether it directly drives disease progression is unclear. Here, we identify co-ordinate epigenetic inactivation of two epithelial-specific transcription factors, EHF and CDX1, as a mechanism driving differentiation loss in CRCs. Re-expression of EHF and CDX1 in poorly-differentiated CRC cells induced extensive chromatin remodelling, transcriptional re-programming, and differentiation along the enterocytic lineage, leading to reduced growth and metastasis. Strikingly, EHF and CDX1 were also able to reprogramme non-colonic epithelial cells to express colonic differentiation markers. By contrast, inactivation of EHF and CDX1 in well-differentiated CRC cells triggered tumour de-differentiation. Mechanistically, we demonstrate that EHF physically interacts with CDX1 via its PNT domain, and that these transcription factors co-operatively drive transcription of the colonic differentiation marker, VIL1. Compound genetic deletion of Ehf and Cdx1 in the mouse colon disrupted normal colonic differentiation and significantly enhanced colorectal tumour progression. These findings thus reveal a novel mechanism driving epithelial de-differentiation and tumour progression in CRC.
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.ispartofseriesCell Death & Differentiation;29
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectEpigenètica
dc.subjectCòlon - Càncer - Aspectes genètics
dc.subjectRecte - Càncer - Aspectes genètics
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/genetics
dc.subject.meshTranscription Factors
dc.subject.meshEpigenesis, Genetic
dc.titleEpithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41418-022-01016-w
dc.subject.decsneoplasias colorrectales
dc.subject.decs/genética
dc.subject.decsfactores de transcripción
dc.subject.decsepigénesis genética
dc.relation.publishversionhttps://doi.org/10.1038/s41418-022-01016-w
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Luk IY, Tse JWT] Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia. La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia. Department of Medicine, University of Melbourne, Melbourne, VIC, Australia. [Jenkins LJ, Schoffer KL, Ng I] Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia. La Trobe University School of Cancer Medicine, Melbourne, VIC, Australia. [Mouradov D] Personalised Oncology Division, The Walter and Eliza Hall Institute of Medial Research, Parkville, VIC, Australia. Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia. [Arango D] Grup de Recerca Biomèdica en Tumors de l'Aparell Digestiu, CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Group of Molecular Oncology, Biomedical Research institute of Lleida (IRBLleida), Lleida, Spain. [Dopeso H] Grup de Recerca Biomèdica en Tumors de l'Aparell Digestiu, CIBBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid35606410
dc.identifier.wos000800969900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record